反应 #816383

反应方程式

pMDI

bromocriptine

bromocriptine mesylate

→

Bromocriptine

反应条件

后处理

1. 1
   其他fitted with a USP induction port (<USP 601> Pharmacopeial Previews 22, 3065 (1995))
2. 2
   过滤filter
3. 3
   其他were actuated per test, with an interval of at least 30 seconds between shots
4. 4
   温度to prevent cooling of the can
5. 5
   其他resultant moisture condensation
6. 6
   过滤filter (corresponding to particles of MMAD less than 3.3 μm)

实验过程

The formulations were tested on an Andersen™ cascade impactor to determine their aerodynamic particle properties. The cascade impactor was operated at 28.3 I/min and fitted with a USP induction port (<USP 601> Pharmacopeial Previews 22, 3065 (1995)). The particle size distributions were fractionated into mass of drug deposited on the pMDI actuator, USP induction port, eight stages and terminal filter. Five shots were actuated per test, with an interval of at least 30 seconds between shots to prevent cooling of the can and resultant moisture condensation. The bromocriptine content in each sample was determined by HPLC. The percentage of the total dose deposited from stage 4 to the terminal filter (corresponding to particles of MMAD less than 3.3 μm) was considered to be the fine particle fraction.

来源